Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation. by Tanaka, Sunao et al.
TitleAlterations of circulating endothelial cell and endothelialprogenitor cell counts around the ovulation.
Author(s)
Tanaka, Sunao; Ueno, Takayuki; Sato, Fumiaki; Chigusa,
Yoshitsugu; Kawaguchi-Sakita, Nobuko; Kawashima,
Ma ahiro; Fujisawa, Noriyoshi; Yoshimura, Kenichi;
Teramukai, Satoshi; Fujiwara, Hiroshi; Fujita, Masatoshi; Toi,
Masakazu
CitationThe Journal of clinical endocrinology and metabolism (2012),97(11): 4182-4192
Issue Date2012-11
URL http://hdl.handle.net/2433/182938




Alterations of Circulating Endothelial Cell and
Endothelial Progenitor Cell Counts around the
Ovulation
Sunao Tanaka, Takayuki Ueno, Fumiaki Sato, Yoshitsugu Chigusa,
Nobuko Kawaguchi-Sakita, Masahiro Kawashima, Noriyoshi Fujisawa,
Kenichi Yoshimura, Satoshi Teramukai, Hiroshi Fujiwara, Masatoshi Fujita,
and Masakazu Toi
Departments of Surgery (Breast Surgery) (S.T., T.U., N.K.-S., M.K., N.F., M.T.), Target Therapy Oncology
(F.S.), Gynecology and Obstetrics (Y.C., H.F.), and Clinical Trial Design and Management, Translational
Research Center (K.Y., S.T.), and Human Health Sciences (M.F.), Graduate School of Medicine, Kyoto
University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
Context: Circulating endothelial cells (CECs) and progenitor cells (CEPs) have been intensively
studied as a promising tool for treating ischemic diseases and monitoring cancer treatments, but
how the menstrual cycle affects the variation in their counts remains unclear.
Objective: The aims of the study were to determine the influence of the menstrual cycle on the
number of CECs and CEPs and to investigate the association of their counts with circulating hor-
mones and angiogenesis-associated factors.
Design: CEP and CEC counts by flow cytometry and the CellSearch system and circulating factor
levels weremeasured eight times during themenstrual cycle in 18 volunteers. Themenstrual cycle
was divided into six phases based on hormone concentrations.
Results: CEP counts peaked in the periovulatory and middle luteal phases with a drop in the early
luteal phase. CEC counts showed no significant variation. There were significant correlations be-
tween the CEP counts and the serum concentrations of estradiol (E2), LH, and granulocyte colony-
stimulating factor (G-CSF) (P 0.0001, P 0.0001, and P 0.01, respectively). Thedifference in CEP
counts between two adjacent phases was significantly correlated with that in E2, LH, G-CSF, and
serum vascular endothelial growth factor (P  0.0001, P  0.0001, P  0.02, and P  0.006,
respectively).
Conclusion: CEP counts peaked in the periovulatory and middle luteal phases, with a drop in the
early lutealphase, andwerecorrelatedwith serumE2, LH,andG-CSF concentrations.Consideration
of the variation in CEP counts would be important for the clinical application of CEPs. (J Clin
Endocrinol Metab 97: 4182–4192, 2012)
The vessel wall controls vascular homeostasis via lin-ing cells and circulating bonemarrow-derived pro-
genitor cells. Over the last decade, various experimental
studies have demonstrated that circulating bone mar-
row-derived progenitor cells are capable of differenti-
ating into mature, functional endothelial cells and in-
ducing neovascularization at the level of the ischemic
tissue, the growing tumor, and the site of wound healing
(1, 2). In particular, a subset of circulating premature
cells, designated as circulating endothelial progenitor
cells (CEPs), is considered to contribute to endothe-
lial cell regeneration and neovascularization.
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CEPs are defined as nonendothelial cells that display
clonal expression and stemness characteristics and differ-
entiate into endothelial cells (3). These cells play multi-
faceted regulatory roles in the adult vascular system and
participate in a number of physiological functions includ-
ing homeostasis, ischemic tissue vasculogenesis, and tu-
mor angiogenesis (4). CEPs were discovered in the 1970s
in a study designed to detect cells that possess the ability
to repair injured denuded vasculature (5). In 1997, CEPs
isolated from peripheral blood were demonstrated to in-
corporate into foci of neovascularization in the adult, pro-
moting processes such as regenerative neoangiogenesis
(1). Recently, CEPs have been studied as a promising tool
for treating ischemic disease and cancer. It has been re-
ported that the introduction of vascular endothelial
growth factor (VEGF)-transduced CEPs into the circula-
tion significantly improved blood flow recovery and cap-
illary density in an ischemic mouse model (6). Transplan-
tation of adult progenitor cells has a beneficial effect on
postinfarction remodeling processes in patientswith acute
myocardial infarction (7). In animal tumor models, inter-
feron--transduced CEPs attenuated tumor growth (8).
To use CEPs in clinical situations, efficient collection of
CEPs from donors would be required. CEPs aremobilized
from the bone marrow to the circulation in response to
cytokines, growth factors, and hormones. It has been re-
ported that some factors such as VEGF, granulocyte col-
ony-stimulating factor (G-CSF), and erythropoietin (Epo)
can induce the differentiation of mobilized stem cells into
CEPs and subsequently enhance CEP proliferation, mi-
gration, and homing to peripheral tissues (9–11). Further-
more, it is known that changes in CEP counts are affected
by hormonal status, body weight, and factors associated
with lifestyle such as smoking, exercise, weight, caffeine,
and alcohol consumption (12). The ovarian sex steroid
hormones estrogen and progesterone are primarily utero-
trophic and control the cyclical patterns of uterine cell
proliferation and vascular growth that occur throughout
the menstrual cycle. Given the synchronized nature of cy-
clic vascularization, it is assumed that angiogenesis-asso-
ciated growth factor expression is induced by steroid hor-
mones to regulate blood vessel formation including that of
CEPs in reproductive organogenesis (13, 14). However,
whether the cyclical systemic variations of these factors
during themenstrual cycle is linked to the variation inCEP
counts is unknown.
Circulating endothelial cells (CECs) are considered as
mature endothelium and generated by vascular turnover.
We reported that CEC counts altered during chemother-
apy in breast cancer patients and that their counts were
associated with the therapeutic response (15). CECs and
CEPs have also been studied as monitoring marker for
treatment response (16).Thus, it is important to clarify the
physiological variation of CECs and CEPs for the clinical
application.
The aims of this study were to determine the influence
of the menstrual cycle on the CEP and CEC counts and to
investigate the association of their counts with circulating
sex steroid or angiogenesis-associated factor levels during
the normal menstrual cycle.
Subjects and Methods
Study population
This study was approved by the institutional ethical commit-
tee, andoral andwritten informed consentwas obtained fromall
volunteers. Eighteen menstruating women (ages, 23–51 yr; av-
erage, 36.3 yr) were recruited for this study. All volunteers were
nonsmokers.
Study design
Peripheral blood samples were collected eight times during
the menstrual cycle to perform CEP and CEC counts and to
measure the concentrations of hormones and angiogenesis-as-
sociated factors from each volunteer. The menstrual cycle was
divided into the following six phases based primarily on hor-
mone concentrations [estradiol (E2), progesterone, LH], basal
body temperature (BBT), and the period of menstruation: 1)
menstrual (M) phase—the period ofmenstruation as declared by
the volunteers; 2) follicular (F) phase—the phase between the
menstrual phase and the periovulatory phase determined by the
criterion described below; the first E2 peak is observed during
the follicular phase; 3) periovulatory (O) phase—estimated ovu-
lation based on hormone levels (immediately after LH surge,
after the first E2 peak, before elevation of progesterone levels)
and BBT (during elevation of BBT). The luteal phase was deter-
mined by the phase between the periovulatory phase and the
menstrual phase in addition to the progesterone peak, the second
E2 peak, high BBT, and the approximate duration of the luteal
phase (approximately 14 d  2 d).
The luteal phase was divided into the following three phases:
4) early luteal (eL) phase—the first third of the luteal phase; 5)
middle luteal (mL) phase—the middle third of the luteal phase;
and 6) late luteal (lL) phase—the last third of the luteal phase.
Bloodwas drawn into 10-ml CellSave tubes (Veridex, LLC,
North Raritan, NJ) for CEP and CEC counts, 5-ml vacuum
tubes (Terumo Corporation, Tokyo, Japan) for serum mea-
surements, and 3-ml EDTA tubes (Terumo Corporation) for
plasma measurements.
Sample preparation
Serum and plasma were obtained from 18 and eight volun-
teers, respectively. Specimens were centrifuged at 3000 rpm for
15 min at 4 C. All samples were aliquoted after collection and
frozen at 80 C until use.
Growth factor, cytokine, and chemokine detection
Plasma concentrations of VEGF and SDF-1 and serum con-
centrations of VEGF, soluble VEGF receptor 1 (sVEGFR1),
sVEGFR2, G-CSF, Epo, placental growth factor (PlGF), endoglin,
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andTie-2were determined using ELISA kits according to theman-
ufacturers’ instructions. The Epo ELISA kit was purchased from
Uscn Life Science Inc. (Wuhan, China), and the other ELISA
kits were purchased from R&D Systems (Minneapolis, MN).
The coefficient of variation was 4.6–6.5% for VEGF, 3.4–
3.9% for SDF-1, 2.6–3.8% for sVEGFR1, 2.9–4.2% for
sVEGFR2, 1.1–2.8% for G-CSF, 3.6–7.0% for PlGF, 2.8–
3.2% for endoglin, and 4.4–5.0% for Tie-2. The cross-reac-
tivity with human proteins was reported not to be significant
for VEGF, SDF-1, sVEGFR1, sVEGFR2, G-CSF, Epo, PlGF,
endoglin, and Tie-2. The VEGF ELISA was reported to be
interfered with by recombinant VEGFR1 and -2 at the con-
centration of 500 and 4000 pg/ml, respectively. Absorbance
was read at 450 nm using a microplate reader (SpectraMax;
Molecular Devices, Sunnyvale, CA). Samples were measured
in duplicate.
Measurement of hormone concentrations
SerumconcentrationsofE2, progesterone, FSH, andLHwere
measured by an electrochemiluminescence immunoassay
method in a Modular E170 automatic analyzer (Roche Diag-
nostics, Mannheim, Germany). The coefficient of variation for
each hormone was less than 10%.
Flow cytometry
Mononuclear cells were isolated by density centrifugation
using Ficoll–Paque Plus gradients (GE Healthcare Bio-Science,
Uppsala, Sweden). Themononuclear cellswere rinsed twicewith
PBS and then incubatedwith allophycocyanin-labeledmonoclo-
nal antihuman CD31 antibody (clone AC 128), fluorescein iso-
thiocyanate-conjugatedmonoclonal antihumanCD34 antibody
(clone AC136), phycoerythrin-conjugated monoclonal antihu-
man CD133 antibody (clone AC133) (all fromMiltenyi Biotec,
Bergisch Gladbach, Germany), and peridinin chlorophyll pro-
tein-conjugated monoclonal antihuman CD45 antibody (clone
2D1; BD Biosciences, San Jose, CA). Samples were finally resus-
pended in 400l of PBS andmeasuredwith a FACSCalibur flow
cytometer (BD Biosciences). The following populations were
considered: CEPs, defined as CD31CD34CD133CD45dim
cells, and CECs, defined as CD31CD45 cells. Data were ex-
pressed as cells per million mononuclear cells (17, 18).
CellSearch system
The standardized CellSearch technique (Veridex, LLC) has
been reported previously (15). Briefly, CECs expressing CD146
were immunomagnetically enriched and stainedwith the nuclear
dye 4,6-diamidino-2-phenylindole, CD105, and CD45. A flu-
orescein isothiocyanate-conjugated anti-CD34 antibody (clone
AC136; Miltenyi Biotec) was used in the additional channel of
the system. Analysis was performed using an image cytometer,
for which CECs were defined as CD146CD105CD45 cells.
Basal body temperature and the period of
menstruation
Each volunteermeasured her BBT everymorning throughout
the menstrual cycle including the days of blood collection. The
period of menstruation was recorded in the body temperature
records.
Statistical analysis
Continuous variables are described asmean SD. The highest
value in each phase was used for the analysis if two or more
measurements were performed in one phase. Datawere adjusted
by dividing each value by the mean value of each factor in each
woman excluding hormone concentrations because variation in
each factor between individuals was large and this adjustment
increased statistical stability, resulting in statistical reliability.
Statistical analysiswasperformedusingWilcoxon’s test for com-
parisons between phases of the menstrual cycle and Pearson’s
correlation coefficient for the correlations between factors. All
analyses were performed using the JMP version 9.0.0 software
package (SAS Institute, Inc., Cary, NC). All P values were two-
sided, and P 0.05 was considered statistically significant. For
multiple comparisons, the Bonferroni correction was applied,
and in the figures, results with statistical significance by the Bon-
ferroni correction are shown in italics and results with P 0.05
are shown in a nonitalic font. The permutation under the null
correlation was performed to further assess the association of
cyclic variation in each factor. A 100,000-permutation test was
performed except for the serum concentration of Epo and the
plasma concentrations of VEGF and SDF-1 due to the small
sample number.
Results
Serum hormone levels during the menstrual cycle
Serum hormone levels were measured in 18 women
volunteers, of whom two women exhibited a perimeno-
pausal hormonal status, one exhibited an anovulatory
hormonal pattern, three did not exhibit a normal hor-
monal pattern, and one took oral contraceptives. Thus, a
total of 11 women were included in the subsequent anal-
yses (ages, 23–45 yr; average, 36.3 yr). BBT in each indi-
vidual is shown in Supplemental Fig. 1 (published on The
Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org). Cyclic alterations of circulating
pituitary and ovarian hormones were confirmed by the
periovulatory peaks for serum E2 and LH concentrations
and by the middle luteal increases for serum E2 and pro-
gesterone concentrations (Fig. 1).
Alterations of CEP and CEC counts during the
menstrual cycle determined by flow cytometry
CEP counts were higher in the O and mL phases than
in the other phases, indicating that CEP counts dropped in
the eL phase after ovulation (O vs. eL, P 0.003; and eL
vs. mL, P  0.01; Fig. 2A). Differences in CEP counts
between two adjacent phases (CEP) were identified by
two peaks in “O–F” and in “mL–eL” (Fig. 2B).
The CEC counts and the differences of CEC counts
between two adjacent phases (CEC) did not exhibit sig-
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nificant alterations during the menstrual cycle (Fig. 2, C
and D).
Alterations of CEC counts during the menstrual
cycle determined by the CellSearch system
Alterations of CEC counts by the CellSearch system
were examined. CEC counts were increased in the mL
phase (eL vs.mL, P 0.02; mL vs. lL, P 0.03; and mL
vs.M, P  0.04; Fig. 2E). CEC in “mL–eL” was larger
than those between other phases (Fig. 2F). The alterations
of CD34-positive CEC counts as determined by the Cell-
Search system were similar to those of the CEC counts by
the CellSearch system (data not shown).
Alterations of angiogenesis-associated factor
levels during the menstrual cycle
The concentrations of angiogenesis-associated factors
during themenstrual cycle are shown in Table 1. The con-
centrationofVEGF in serumwas significantly lower in the
lL phase (O vs. lL, P 0.003; M vs. lL, P 0.01; and eL
vs. lL, P  0.01; Fig. 3A). The concentration of VEGF in
plasma was lower in the F phase than in the other phases
(M vs. F, P  0.02; F vs. O, P  0.03; and F vs. lL, P 
0.045; Fig. 3C). The concentrations of serum G-CSF var-
ied throughout the menstrual cycle. The concentration of
G-CSF was higher in the O phase than in the other phases
(O vs. M, P  0.042; Fig. 3E).
FIG. 1. Serum hormone levels during the menstrual cycle (A, E2; B, progesterone; C, LH; D, FSH). Normal menstrual alterations are indicated by
the O phase peaks in serum E2 and LH concentrations, and the mL phase increases in serum E2 and progesterone (Prog) concentrations. The
individual values are presented as dots.
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FIG. 2. The alterations of CEP and CEC counts during the menstrual cycle. The counts of CEPs, defined as CD31CD34CD133CD45dim cells,
increased in the O and mL phases (A), and the CEC counts determined by the CellSearch system increased in the mL phase (E). The counts of CEC,
defined as CD31CD45 cells, did not exhibit such a pattern (C). The difference in counts between two adjacent phases was indicated by  (CEP
and CEC) (B, D, and F). P values with statistical significance by the Bonferroni correction are shown in italics.
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The concentrations of other factors including PlGF,
SDF-1, sVEGFR1, sVEGFR2, Epo, endoglin, and Tie-2
did not exhibit any significant patterns during the men-
strual cycle (Table 1).
Correlations between CEP counts and the
concentrations of hormones and other
angiogenesis-associated factors during the
menstrual cycle
There were correlations between CEP counts and E2,
LH, and G-CSF concentrations (r 0.47, P 0.0001, in
Fig. 4A; r  0.46, P  0.0001, in Fig. 4C; r  0.32, P 
0.01, in Fig. 4E, respectively).Correlations betweenCEP
and E2, LH, G-CSF, and VEGF were also observed
(r  0.58, P  0.0001, in Fig. 4B; r  0.49, P  0.0001,
in Fig. 4D; r  0.30, P  0.02, in Fig. 4F; r  0.34, P 
0.006, in Fig. 4H, respectively). There was also a corre-
lation between the concentration of G-CSF and that of E2
(r0.31;P0.01; datanot shown).Thepermutation test
further supported the correlation of CEP counts with E2,
LH, and G-CSF concentrations (P  0.001, P  0.025,
and P  0.014, respectively) (Table 2). In addition, CEP
counts exhibited correlations with serumVEGF and PlGF
levels (P  0.016 and P  0.008, respectively) (Table 2).
Discussion
Components of the female reproductive system undergo a
numberofprogrammedangiogenicprocesses that are cou-
pled with the cyclic evolution and decline of the ovaries
and endometrium. In the normal ovary, angiogenesis
likely plays an important role in folliculogenesis, ovula-
tion, and corpus luteum function.At the timeof ovulation,
the basement membrane separates the highly vascular
theca cell layer from the avascular granulosa cell layer
lining the inside of the follicular degenerates, and dynamic
capillary growth occurs directed inward from the theca.
Consequently, the most intensive angiogenesis can be de-
tected during the periovulatory period. The dynamic
growth is completed by the end of the third day after ovu-
lation, and this may explain the O phase peak and the
subsequentdropofCEPcounts in the eLphase,whichmay
be a reflection of CEP consumption during the ovulatory
phase. A previous study determined that vascular space
within the human corpus luteum increased from the eL to
mL phase, which may explain the mL phase increase of
CEPs (19). Similar to the ovary, the endometrial vascular
architecture changes throughout the menstrual cycle in
parallel to the changes in the uterine epithelium and
stroma. During the late F phase and throughout the luteal
phase, a complex subepithelial capillary plexus develops,
which may also be associated with the mL phase peak of
CEP counts. BecauseCEPs are derived from the bonemar-
row but CECs are from existing vasculature, CECs do not
seem to show a changing pattern similar to that of CEPs.
Recent studies have provided evidence that the phys-
iological cycle of estrogen regulates CEP kinetics; i.e.
differentiation, proliferation, migration, apoptosis,
mobilization, and ultimately incorporation into foci of
neovascularization in the developing endometrium (20,
21). It is known that estrogen increases the growth of
culturedCEPs isolated fromhuman peripheral blood. In
humans, CEP counts are increased by hormone replace-
ment therapy consisting of an E2-based medication and
the progesterone-derived drug norethisterone (22).
Consistently, premenopausal women have higher CEP
counts than postmenopausal women (22). E2 also af-
fects the production of key proangiogenic factors such
as VEGF (23) and G-CSF (24), which have been sug-
gested to increase CEP counts. These findings support
our result of a significant correlation between CEP
counts and serum E2 concentrations.
TABLE 1. Angiogenesis-associated factor concentrations during phases of the menstrual cycle
M F O eL mL lL
n 11 11 11 11 11 10
Serum
G-CSF (pg/ml) 21.95  10.17 24.79  23.99 30.95  14.42 27.85  14.02 28.88  12.60 20.41  10.89
VEGF (pg/ml) 303.22  211.50 266.69  164.65 304.37  164.65 297.03  187.33 269.42  163.80 257.93  177.37
Endoglin (ng/ml) 2.80  1.00 2.68  1.05 2.57  1.18 2.44  0.94 2.58  1.02 2.59  1.26
sVEGFR1 (pg/ml) 83.54  34.88 76.97  27.81 78.11  32.35 73.10  33.78 83.34  27.34 78.81  30.57
sVEGFR2 (pg/ml) 7,993.05  5,016.75 5,969.84  1,952.22 6,344.88  1,445.76 6,128.06  2,056.42 5,946.17  1,684.39 5,976.91  1,663.18
Tie-2 (ng/ml) 13.98  1.91 11.73  1.50 12.31  1.58 12.05  1.50 12.95  1.78 12.64  1.85
PlGF (pg/ml) 11.25  1.23 11.24  1.29 11.00  0.96 10.03  1.33 10.54  0.87 10.28  1.40
Epo (pg/ml)a 1,318.0  1,833.7 8,245.4  22,503.3 8,015.4  2,138.8 17,451.1  46,226.6 3,157.4  7,188.2 3,964.6  9,500.7
Plasma
SDF-1 (pg/ml)b 2,351.45  304.73 2,265.12  423.59 2,265.82  421.437 2,235.64  358.534 2,292.49  470.017 2,255.68  471.45
VEGF (pg/ml)b 33.74  4.49 26.02  3.68 34.36  1.93 29.93  4.84 29.95  3.53 36.15  6.55
Values are reported as mean  SD.
a Epo levels were not measured in one volunteer.
b The concentrations of SDF-1 and VEGF in plasma were measured in six samples.
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VEGF is a protein with growth-promoting activity in
vascular endothelial cells. Several studies suggest that
VEGF plays important roles in angiogenesis in the female
reproductive tract (25, 26). It is known that estrogen in-
creases VEGF expression in uterine tissues, endothelial
cells, and vascular smooth muscle cells (27, 28). In this
study, the levels of VEGF in plasma decreased in the F
phase and increased in the O phase; this is similar in pat-
FIG. 3. The alteration of VEGF in plasma and serum and G-CSF levels during the menstrual cycle. The level of VEGF in plasma was lower in the F
phase (C). The level of VEGF in serum was higher in the O phase and lower in the lL phase (A). The levels of G-CSF increased in the O phase (E).
The difference in concentrations between two adjacent phases was indicated by  (VEGF and G-CSF) (B, D, and F). P values with statistical
significance by the Bonferroni correction are shown in italics.
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tern to that of the variation of E2 levels.
Because there are some conflicting re-
sults regarding VEGF variations
throughout the menstrual cycle (29),
further studies are required to investi-
gate the association of the variation of
VEGF levels with the menstrual cycle.
In agreement with our finding, some
studies reported that serumG-CSF con-
centrations were higher in the ovula-
tory phase than in the other phases (30,
31), suggesting that G-CSF is associ-
atedwithovulation.Wealso found that
G-CSF levels were correlated with E2
levels. A previous study demonstrated
that mice injected ip with E2 exhibited
increased levels of G-CSF in the bron-
choalveolar lavage, suggesting that E2
affects G-CSF levels in vivo (24). In this
study, the alteration of G-CSF levels
was similar to that of CEP counts (Fig.
4). Mice that received recombinant hu-
man G-CSF exhibited elevated CEP
counts (11, 32). Patients with chronic
ischemic heart disease who receive G-
CSF have increased CEP counts (33).
G-CSF was reported to activate the
VEGF/VEGFR1 pathway and to pro-
mote CEP mobilization in vivo (34).
These findings raise the possibility that
G-CSF increases CEP counts either di-
rectly or indirectly.
Recently, the clinical applications of
CEPs were investigated. It was reported
that autologous progenitor cell trans-
plantation can be used for the treatment
of patients with acutemyocardial infarc-
tion (7). CEPs also have potential uses in
anticancer treatment as a vehicle for the
delivery of toxic genes, suicide genes, an-
ticancer drugs, and angiogenesis inhibi-
tors (35). The efficient collectionofCEPs
would be critical for such clinical appli-
cations. Our results suggest that consid-
eration of the menstrual cycle (e.g. col-
lection in the mL phase) would increase
the efficiency of CEP collection. In addi-
tion, CEPs and CECs have been studied
asbiomarkers for tumorprogressionand
for monitoring therapeutic effects (15,
16). The consideration of the physiolog-
ical variationofCEPs is required for such
FIG. 4. Correlation between CEP counts and the levels of hormones and angiogenesis-
associated factors. There were correlations between CEP counts and serum E2 (A), LH (C),
and G-CSF (E) concentrations (P  0.0001, P  0.0001, and P  0.01, respectively). No
correlation was observed between CEP counts and serum VEGF concentrations (G) (P 
0.10). There were correlations between differences in CEP between two adjacent
phases (CEP) and differences in serum E2 (E2) (B), LH (LH) (D), G-CSF (G-CSF) (F),
and VEGF (VEGF) (H) concentrations between two phases (P  0.0001, P  0.0001,
P  0.02, and P  0.006, respectively). A, C, E, and G, E  M,   F,   O,   eL,
‚  mL, Y  lL. B, D, F, and H, E  M–lL,   F–M,  O–F,   eL–O, ‚  mL–eL,
Y  lL–mL.
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applications. However, because it is unknown whether the
alterationsofCEPcounts inpatientswith ischemicdiseaseor
cancer are similar to those in healthy people, such studies are
warranted for clinical considerations.
There are inconsistent results regarding the variation of
CEP levels during the menstrual cycle (36–40). These dif-
ferences could be due to differences in determining the
phases in the menstrual cycle, the frequency of blood col-
lection, identifying markers for CEPs, standardization of
the data, and selection of healthy women with a normal
menstrual cycle. Our study employed the most frequent
sampling among studies reported, enabling more reliable
data in terms of determining the phases of the menstrual
cycle. The frequent collection also enabled disclosure of
more precise alterations of CEP counts and angiogenesis-
associated factors during the menstrual cycle. There is a
controversy regarding the surface markers that identify
CEPs. The identification of a unique combination of
markers specific and selective for primary endothelial pro-
genitor cells would promote studies on the clinical and
biological features of CEPs.
One of the biggest limitations of this study is its small
sample size. This study recruited 18 healthy volunteers,
which is the largest number of volunteers among reported
studies, and seven volunteers who did not show a normal
hormonal pattern were excluded from the analysis be-
causewe believe that strict determination of themenstrual
cycle is crucial for the reliable analysis. The large variation
in each factor between individuals is another limitation.
To increase the statistical stability and the reliability of
data, we have adjusted the data by dividing each value by
the mean value in each individual. In addition, to avoid
false significance, we have used the Bonferroni correction
andperformeddifferent statistical analyses to corroborate
the analytical results. Additional research with a larger
sample size is necessary to validate the present study.
In conclusion, we demonstrated that CEP counts
peaked in theOandmLphaseswith adrop in the eLphase,
and were closely correlated with serum E2, LH, and G-
CSF concentrations. Additional studies are required to
further clarify the clinical andbiological significanceof the
fluctuations of CEP counts during the menstrual cycle.
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